NEWS
Paul Hastings Advises Underwriters in Lexeo Therapeutics’ Public Offering and Concurrent Private Placement
October 17, 2025
Paul Hastings LLP advised Leerink Partners, Cantor, Stifel, Oppenheimer & Co. and Baird in connection with Lexeo Therapeutics’ underwritten public offering. In addition, the firm advised Leerink Partners as placement agent in Lexeo’s concurrent private placement.
Lexeo offered 15,625,000 shares of its common stock in the public offering, at an offering price of $8.00 per share. Concurrent with the public offering, Lexeo agreed to sell pre-funded warrants to purchase 1,250,015 shares of common stock to Balyasny Asset Management at a price of $7.9999 per pre-funded warrant in a private placement. The public offering and concurrent private placement are expected to close on Oct. 20, 2025, subject to customary closing conditions.
Partner Will Magioncalda and of counsel Ryan Brewer led the Paul Hastings team, which included associates Chris Guerin and Adam Swank.
More details can be found here.
About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.